bis(4,7- dimethyl- 1,10- phenanthroline)sulfatooxovanadium(IV)

structure in first source
Also Known As:
(VO(SO4)(Me2-phen)2); metvan
Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Uckun, F M: 3 articles (07/2001 - 03/2000)
2. Dong, Y: 3 articles (07/2001 - 03/2000)
3. Narla, R K: 3 articles (07/2001 - 03/2000)
4. D'Cruz, Osmond J: 1 article (12/2002)
5. Uckun, Fatih M: 1 article (12/2002)
6. Chen, C L: 1 article (07/2001)
7. Klis, D: 1 article (04/2001)
8. Sudbeck, E: 1 article (03/2000)

Related Diseases

1. Neoplasms (Cancer)
2. Glioblastoma (Glioblastoma Multiforme)
3. Breast Neoplasms (Breast Cancer)
07/01/2001 - "At this dose level, the maximum plasma METVAN concentration was 37.0 microM, which was achieved with a t(max) of 21.4 min. Plasma samples (diluted 1:16) from METVAN-treated mice killed 85% of human breast cancer cells in vitro. "
12/01/2002 - "Metvan exhibits significant antitumour activity, delays tumour progression and prolongs survival time in severe combined immunodeficient mouse xenograft models of human malignant glioblastoma and breast cancer. "
07/01/2001 - "METVAN was slowly eliminated with an apparent plasma t(1/2) of 17.5 h and systemic clearance of 42.1 ml/h/kg. In accordance with its potent in vitro activity and favorable in vivo pharmacokinetics, METVAN exhibited significant antitumor activity and delayed tumor progression in CB.17 severe combined immunodeficient (SCID) mouse xenograft models of human glioblastoma and breast cancer. "
12/01/2002 - "At nanomolar and low micromolar concentrations, metvan induces apoptosis in human leukaemia cells, multiple myeloma cells and solid tumour cells derived from breast cancer, glioblastoma, ovarian, prostate and testicular cancer patients. "
12/01/2002 - "Treatment of leukaemia cells from acute lymphoblastic leukaemia, acute myeloid leukaemia and chronic acute myeloid leukaemia patients with metvan inhibits the constitutive expression as well as the gelatinolytic activities of matrix metalloproteinase-9 and -2. Treatment of human malignant glioblastoma and breast cancer cells with metvan at concentrations > 1 microM is associated with a nearly complete loss of the adhesive, migratory and invasive properties of the treated cancer cell populations. "
4. Multiple Myeloma
5. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

Related Drugs and Biologics

1. Matrix Metalloproteinase 9 (Gelatinase B)
2. Reactive Oxygen Species (Oxygen Radicals)
3. Sultan

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)